MAPT and Alzheimer disease: Since Aβ, tau, α-synuclein, and prion fibrils all contain similar β-sheet structures, FDDNP labeling potentially indicates a broad-spectrum of pathologies in vitro, but with preferential binding to tau in AD brains.